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under the CC BY-NC-ND license (http:Abstract Introduction: In the management of upper tract urothelial cell carcinoma (UTUC)
endoscopic, nephron sparing procedures like ureterorenoscopy (URS) or percutaneous tumour
resection (PCTR) still play a very limited role. This could lead to possible unnecessary radical
nephroureterectomies (RNU), still being the gold standard treatment. The risk of chronic
kidney disease (CKD) later in life is important. In this study we present the results of
24-year experience with PCTR in a single institution.
Methods: We identified 44 patients who underwent PCTR between 1992 and 2015. Radical
resection was achieved in 40 patients who were included in this study. Demographic and
clinical data, including tumour recurrence, progression to RNU, tumour grade and overall
survival (OS) were retrospectively acquired. An outcome analysis was conducted.
Results: Median age at diagnosis was 68 years (range 42e94 years). Low grade tumours were
found in 37 patients (92.5%) and high grade tumours in three patients (7.5%). Median follow-
up was 53 months during which 20 patients developed upper tract recurrences (50.0%). The
longest time to recurrence was 97 months. At follow-up 11 patients (27.5%) underwent an
RNU and two patients died from UTUC. RNU could be avoided in 29 patients (72.5%). In this
study we found that multifocality is a significant risk factor for recurrence, but not for stage
progression to RNU.
Conclusion: PCTR is a surgically and oncologically safe procedure. Renal preservation in
patients with UTUC who are eligible for percutaneous resection can be achieved in the major-
ity of patients. Selection criteria for PCTR should be further refined, leading to a wider appli-
cation of PCTR in the future. Follow-up needs invasive procedures and should be long term.
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Endoscopic treatment of upper tract urothelial cell carci-
noma (UTUC) arose in 1985, when Huffman et al. [1] re-
ported on a ureteroscopic tumour resection. In 1986 Streem
and Pontes [2] reported on the first percutaneous approach
for the treatment of UTUC [2]. Experience with endoscopic
treatment of UTUC has historically been limited to a few
centres worldwide, treating sub-groups of patients with
imperative indications for non-removal of renal units,
either ureteroscopically with laser ablation techniques
or percutaneously with electro-resection. With increasing
experience endoscopic management has been extended to
selected patients with elective indications in a few centres.
UTUC is a very rare disease [3,4]. It occurs in 2%e5% of
all urothelial cell tumours. An increase can be seen in the
Netherlands since 2005 of 1e1.5 per 100,000 inhabitants
per year.
Radical nephroureterectomies (RNU) is considered the
“gold standard” treatment for UTUC because of its often
advanced stage and aggressive nature at presentation [5].
Conservative management for UTUC has been used for pa-
tients with solitary kidneys, end stage chronic kidney dis-
ease (CKD), bilateral UTUC or patients in poor surgical
condition. But the question arises whether conservative
treatment is an option in the presence of a normal contra
lateral kidney. Is it possible to use treatment algorithms
akin to the conservative treatment options for non invasive
bladder cancer? In renal cell carcinoma (RCC) nephron
sparing surgery is widely used for better overall survival
(OS) due to preservation of kidney function and reduced
risk for CKD [6e8]. A loss of kidney function after RNU is
obvious. Nephron sparing surgery for UTUC will most likely
have a better OS as well. But which patient is suitable for
conservative treatment? Several studies have addressed
this question [9,10]. The recently published EAU guideline
on urothelial cell carcinoma of the upper urinary tract
indicates that conservative treatment can be discussed
in low-risk patients with a functional contra lateral kidney
avoiding the morbidity associated with open or laparo-
scopic radical surgery and not compromising oncological
outcomes and kidney function [11]. Sixty percent of
patients with UTUC present with invasive disease, as
compared with only 15%e20% of patients with bladder
cancer [12].
This underlines the need for proper patient selection. In
2015 Motamedinia et al. [10] presented a large study in
which they conclude that nephron-sparing endoscopic
resection continues to be an increasingly relevant choice
for the management of patients with UTUC.
With this study we intend to support this view whole
heartedly and contribute to determining selection criteria
for patients who could or even should undergo percuta-
neous tumour resection (PCTR) for the treatment of UTUC.
2. Patients and methods
2.1. Patients
This study received local Institutional Review Board
approval. A retrospective analysis was performed of allpatients treated with PCTR of urothelial carcinoma of the
kidney and/or proximal ureter between 1992 and 2015. In
1995 we reported on the first 10 patients treated with PCTR
in our centre [13]. The files of four of these patients were not
retrievable. These patients are not included in this study.
A total of 190 patients with an initial diagnosis of UTUC
were identified of whom 44 patients underwent PCTR.
Imperative indications for endoscopic treatment were a
solitary kidney, risk of developing of CKD, bilateral disease
and a poor physical condition due to co-morbidity and/or
age.
The chance of developing CKD was dependent on a
multitude of factors such as serum creatinine, body mass
index, diabetes mellitus and cardiovascular status. An
exact cut-off level of creatinine was not used in our study.
2.2. Pathology and cytology
Tumours were classified as low or high grade according to
the WHO grading criteria [10]. Earlier cohorts of patients
who were classified using the WHO 1973 grading criteria
were reclassified as low grade in case of grade 1 or 2 and as
high grade in case of grade 3. Urine cytology results were
determined.
2.3. Patient selection and technique
Patient selection for PCTR was based on imaging of the
renal collecting system. The continuity and integrity of the
collecting system wall at the tumour location has always
been the determining factor for eligibility for PCTR. With
the availability of flexible ureteroscopes a diagnostic ure-
terorenoscopy (URS) was performed for confirmation of the
findings on imaging. Small tumours that could be coagu-
lated were treated in the same session.
All patients were treated in a percutaneous neph-
rolithotomy (PCNL) setup in prone position. In case of
hydronephrosis access to the collecting system was reached
by puncture using ultrasonic guidance without the need for
a contrast medium. If the kidney was not dilated a ureteral
catheter was placed ipsilaterally and a diluted contrast
medium was used to induce a mild dilatation. After the
ultrasonically guided puncture a percutaneous tract was
then established by dilatation using the Alken dilators, thus
having exact control over the extent of dilation into the
lumen of the collecting system. The nephrostomy tract was
dilated up to 28 Fr outer diameter. The inner diameter of
the Amplatz sheath was 26 Fr. Resection of the tumour was
performed with a 23.5 Fr Olympus resectoscope. Only the
inner shaft without the continuous flow outer shaft was
used. A slightly elevated pressure in the collecting system
was created by the narrow space between the resectoscope
and the Amplatz sheath and a water pressure of approxi-
mately 80 cm at the inflow site. This caused the dilatation
needed during resection. Handling of the resection loop
was done with great care to avoid touching non tumour
afflicted parts of the pelvic wall, hence the need for a slight
dilatation. It was necessary to estimate the depth of each
cut using the effects on the tumour base of moving the
tumour with the loop, without the application of cutting
power. Each tumour chip was removed from the collecting
Table 1 Patient demographics, tumour characteristics
and complications (n Z 40).
Variable Value
Age (year)a 68 (42e94)
Gender
Male 26 (65.0)
Female 14 (35.0)
Laterality
Right 22 (55.0)
Left 18 (45.0)
History of urothelial cell carcinoma 15 (38.0)
Imperative indications 20 (50.0)
Charlson co-morbidity index
0 3 (7.5)
1 11 (27.5)
2 12 (30.0)
3 11 (27.5)
4 2 (5.0)
5 1 (2.5)
Complications (Clavien Dindo)
0 26 (65.0)
1 5 (12.5)
2 6 (15.0)
3 1 (2.5)
4 2 (5.0)
5 0 (0)
Recurrence 20 (50.0)
Time to recurrence (month)a 13 (2e97)
Progression to RNU 12 (30.0)
Time to RNU (month)a 17 (5e66)
Follow-up (month)a 53 (3e217)
RNU, radical nephroureterectomies.
a Value expressed as median (ranges), others as n (%).
Figure 1 KaplaneMeier curve of recurrence-free survival.
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became visible indicating that the base of the tumour was
resected. Careful coagulation was performed of the entire
tumour afflicted area after resection. The power settings
were the same as those used for bipolar bladder tumour
resection (280 W cutting and 80 W coagulating). Because
the chance of an arterial lesion is greater with PCTR than
with PCNL an angiography suite with staff was always
standby during a PCTR procedure in order to perform an
emergency (selective) embolization in case of an incon-
trollable bleeding.
After the procedure a 24 Fr nephrostomy tube was
placed. Some patients received post operative antegrade
instillation of mitomycin C (MMC) or Bacille Calmette Guerin
(BCG). All patients were treated by a single surgeon only.
2.4. Follow up
Patients were evaluated every 3e4 months for 2 years
and then annually for 5 years. Follow-up visits included a
history, urine cytology, cystoscopy and upper tract imaging
using retrograde ureteropyelography or a computed
tomography-intravenous urography (CT-IVU). In most pa-
tients a flexible ureterorenoscopy was performed at
3 months and then yearly for 2 years. In case of recurrence
the follow-up was changed accordingly. Tumour recurrence
was defined as tumour in the ipsilateral kidney or ureter
after complete initial resection(s).
2.5. Statistical analysis
All data were analyzed using SPSS version 23 (IBM, North
Castle, New York, USA). Recurrence free survivals (RFS) was
calculated using the KaplaneMeier analysis and Cox pro-
portional hazards models were used for predictors of
recurrence or stage progression to RNU. P values less than
0.05 were considered statistically significant.
3. Results
During a 24-year period, 44 primary percutaneous resections
were performed. Macroscopic radical resection occurred
in 40 patients (90.9%). In two of these 40 patients a second
PCTR was necessary in order to obtain a radical resection.
This procedure was done during the same hospital stay.
An incomplete resection occurred in four patients.
These were excluded for further analysis. The tumour
afflicted part of the pelvic wall was too large for a safe or
complete resection. Two of these patients received palli-
ative treatment due to age and co-morbidity and two had a
RNU. The delay of the RNU did not alter the cancer specific
survival (CSS) of these patients, who are still alive without
tumour recurrence.
Table 1 shows the patient demographics. The median
age at diagnosis was 68 years (mean 69 years). Anatomical
or functional mono kidney was present in 10 patients
(25.0%). A prior history of urothelial cancer was noted in 15
patients (37.5%), of whom three patients had a cystectomy
and six patients had nephroureterectomy. A Charlson co-
morbidity index score of 0 was only present in three pa-
tients (7.5%) and a score of or more than 3 was present in 14patients (35.0%). Of the 40 patients with a radical resection
20 patients were referred. The follow-up was performed by
the referral centres causing omissions in follow-up data.
The median follow-up was 53 months (3e217 months).
Twenty patients (50.0%) developed an upper tract
recurrence during follow-up (Fig. 1). The median time to
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patients could be treated by conservative treatment (flex-
ible URS with laser coagulation or secondary PCTR). RNU
was performed in 12 patients (30.0%). The median time to
RNU was 17 months (5e66 months). One patient had an RNU
which did not show any tumour. In this patient the indica-
tion to RNU was made based on imaging. URS was not
possible due to urinary diversion surgery. Two patients did
not receive any more curative treatment due to co-
morbidity or age. Both patients had a history of urothelial
cell cancer which resulted in a cystectomy in one and
nephroureterectomy in the other. One patient died of
metastatic disease. The other patient is still alive 63
months after percutaneous resection. This patient also
developed a tract metastasis which was locally resected.
Two patients died of other causes before secondary treat-
ment could be performed. During the follow-up a total of 19
patients (47.5%) died.
Of the 23 patients referred from other centres, 20 had
an imperative indication for conservative treatment. A
patient flowchart is shown in Fig. 2. In 15 patients there
was a medical history of urothelial cancer. This had lead to
a nephroureterectomy in six patients, cystectomy in four
patients and the other patients had multiple transurethral
resections of a bladder tumour.
Complications were seen in 14 patients (35.0%). A
complication with a Clavien Dindo score of 3 or more
occurred in three patients (7.5%), two due to bleeding, one
due to myocardial infarction. Selective embolization was
necessary in one patient. There were no surgery related
deaths.
High grade tumours were found in three patients (7.5%)
and low grade in 37 patients (92.5%). Of the four patients
who were not radically resected, one patient had a highFigure 2 Patient flowchart. UTUC, upper tract urothelial cell c
ectomy; PCTR, percutaneous tumour resection.grade tumour. Urine cytology was performed in 34 patients
and was malignant in only one patient. This was a patient
with a high grade tumour.
Statistical analysis showed that multifocality is a signif-
icant risk factor for developing recurrence, but not for
stage progression to RNU. No significance was shown for
age, gender, grade, medical history of urothelial cell
carcinoma (UCC) or solitary kidney for recurrence or stage
progression to RNU (Tables 2 and 3).4. Discussion
In this study the results of 40 patients treated with percu-
taneous resection for UTUC are presented. We acknowl-
edge the small number of patients. This small number of
patients is due to rarity of UTUC and the aggressive nature
at presentation which limits the chance of conservative
treatment even further, while RNU is a safe alternative
with a good oncological outcome. Patients with imperative
indications do not have this alternative, which can cause a
bias in indications for PCTR.
In our study we did not see a relation between impera-
tive cause and recurrence or stage progression to RNU.
In general the management of patients with UTUC often
challenges one of the foremost urologic principals, which
is to preserve as many nephrons as possible. For elderly
patients with co-morbidity and a direct risk for CKD this is
clear, but should not nephron sparing surgery be performed
in every suitable patient (with a normal contralateral kid-
ney)? There are no studies in which risk actors for OS, CSS,
RFS and morbidity have been established for endoscopic
treatment. Cutress et al. [9] reviewed the relevant litera-
ture published until 2011. All studies were retrospective.arcinoma; URS, ureterorenoscopy; RNU, radical nephroureter-
Table 2 Cox proportional hazard analysis model predict-
ing recurrence.
Variable HR (95% CI) p-Value
Age (per year) 0.98 (0.94e1.02) 0.38
Gender (male) 1.30 (0.50e3.40) 0.59
Multifocal 8.69 (2.39e31.5) 0.001
Grade 2.04 (0.59e7.09) 0.26
Medical history of UCC 1.25 (0.51e3.08) 0.62
Mono kidney 0.95 (0.34e2.60) 0.91
HR, hazard ratio; CI, confidence interval; UCC, urothelial cell
carcinoma.
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resecting tumour tissue than URS, the latter in general
allowing only for laser coagulation.
Our retrospective study data were biased because the
follow-up scheme could not be reliably controlled in all of
the referring centres due to the lack of a generally applied
follow-up protocol.
Of the 40 radically resected patients, 25 patients
retained their kidney at follow-up without residual or
metastatic disease. Eleven patients had a secondary RNU
after local tumour recurrence. Pathology revealed only four
patients with high grade tumour and/or muscular invasion,
suggesting that the other seven patients could have been
treated conservatively with re-PCTR or URS.
4.1. Size and multifocality
According to the present European Guidelines multifocality
and tumour size >1 cm are contra indications for endo-
scopic treatment. PCTR is only mentioned as a treatment
option in patients who have a low risk, non-invasive tumour
in the lower pole of the collecting system due to the diffi-
culty reaching it ureteroscopically [11]. In some studies it
has been suggested that multifocality is a risk factor [14,15]
but statistical significance in endoscopic series was not
achieved [10,16,17]. In this study it was found that multi-
focality is a significant risk factor for recurrence, but not
for stage progression to RNU.
We believe that multifocality or tumour size is irrelevant
if radical resection can be obtained.
In RCC partial nephrectomies have followed a pattern of
increasing tumour sizes that could be removed. The future
will tell if a similar pattern with UTUC will occur.Table 3 Cox proportional hazard analysis model predict-
ing stage progression to RNU.
Variable HR (95% CI) p-Value
Age (per year) 0.99 (0.94e1.05) 0.69
Gender (male) 0.53 (0.16e1.74) 0.29
Multifocal 2.66 (0.57e12.4) 0.21
Grade 1.11 (0.14e8.70) 0.92
Medical history of UCC 1.07 (0.31e3.68) 0.91
Mono kidney 0.29 (0.04e2.28) 0.24
HR, hazard ratio; CI, confidence interval; RNU, radical neph-
roureterectomy; UCC, urothelial cell carcinoma.4.2. Patient selection
In our experience, the tumour appearance on imaging is the
determining factor for eligibility for endoscopic treatment
in general. The extent of the tumour could not always
be properly established however. A diagnostic URS can give
extra information on the extent of tumour, but cannot
always preclude that the tumour afflicted area is too large
to be completely resected in one session. However, URS is
not always possible in patients with urinary diversion and
imaging or percutaneous inspection will be the only tools to
see if PCTR is possible.
In our study we only had three high grade tumours
suggesting a correlation between non-infiltrative tumour
appearance on imaging and low grade tumours.
Doubts about the non-invasiveness on imaging can result
in an increased chance that the tumour cannot be completely
resected, even when thorough inspection after resection
shows no residual tumour. Microscopic invasion can obviously
not be seen on imaging. The fact however that the entire
afflicted part of the pelvic wall should be either completely
resected or completely coagulated (as opposed to what can
be seen in bladder tumour resections) makes microscopical
invasion less relevant. There were four patients in our group
of whom the UTUC could ultimately not be radically resec-
ted. Imperative indications biasedproperpatient selection in
all of these cases, while imaging was obviously not sufficient.
In our series the presence of tumour in the peripelvic
fatty tissue on pathological examination would mean that
tumour was left behind, leading to an RNU. However this
never happened in our cohort, underlining the value of
imaging in patient selection.
4.3. Follow-up
The longest time to recurrence was 97 months. Long-term
follow-up is therefore mandatory. We still do not know if
the follow-up for patients successfully treated with PCTR
should be 5 or 10 years. We find that the invasive nature of
the follow-up scheme is a burden for some patients due to
the possible need of multiple URS procedures with anaes-
thesia. In our series a first URS was performed 3 months
after PCTR. The findings at this inspection determined the
frequency of URS procedures during follow-up. The prog-
nostic value of multifocality and tumour grading is still
debatable [10], but it can be used to “intensify” the follow-
up. The earlier tumour recurrences are found the smaller
they are, which improves the chance of a curative ure-
teroscopic coagulation, avoiding a more invasive PCTR.
Tumour progression in the case of a recurrence is rare
[18] as can be seen in our series. One of 40 patients (2.5%)
died of metastasis after progression to RNU. We suggest the
use of a follow-up protocol as described above, which
evaluated in the course of the years. Retrograde urography
as imaging modality is preferred over CT urography if
possible, the former having the lowest X-ray exposure.
4.4. Preoperative biopsies
We believe that, even when there are no imperative in-
dications, tumour grade should not influence the decision
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as a whole can be completely resected. The chance of
recurrence appears to be higher. The question remains if a
re-do endoscopic treatment or delayed RNU alters the CSS
or OS [19e21]. The answer to this question can only be
acquired by a randomized controlled trial for patients
suitable for endoscopic treatment.
Preoperative biopsies should not alter the treatment
plan and preoperative URS should therefore be done in
order to confirm the findings on imaging, assess the tumour
area and to exclude unexpected findings, not primarily for
biopsies. Pathology reports on tumour stage and grade are
more reliable with tissue obtained after PCTR than with
ureteroscopically achieved biopsy material and therefore
the decision on proceeding with RNU can be more soundly
made. The disadvantage of a possible second operation
does not outweigh the chance of renal preservation with
diminished chances of CKD later in life. In Fig. 3 an algo-
rithm is shown, used in our clinic. Patient counselling
influences the choice of treatment. If the patient is eligible
for PCTR a proper and uniform counselling of the treatment
options is important. Some patients will choose RNU as first
treatment option. Others have chosen RNU after the first
recurrence and even after successful PCTR, due to the
burden of invasive surveillance.Figure 3 Treatment algorithm for UTUC in Zuyderland MC in the
ureterorenoscopy; RNU, radical nephroureterectomy; res., residua4.5. BCG or MMC
The influence of postoperative instillation with BCG or MMC
in the collective system has not been assessed in our study.
We did not systematically instillate the upper tract due to
the risk of complications after resecting part of the pelvic
wall and therefore allowing infiltration of peripelvic fatty
tissue. In one patient with a solitary kidney we found what
appeared to be seeding recurrence in the ureter after
PCTR, necessitating frequent URS treatments, ultimately
leading to strictures and finally RNU.
The question arises whether the urothelial cell in the
upper urinary tract behaves the same as in the lower
urinary tract. If so than the same risk calculators for the
bladder would be sufficient for the kidney. A single ante-
grade MMC instillation after resection would be advisable to
reduce the chance for recurrence. In our institution a single
antegrade admission of MMC after each PCTR after sealing
of the collecting system (no leakage on antegrade contrast
imaging) has been applied in the last 2 years.
After a curative resection of a high grade tumour adju-
vant BCG in 6 weekly admissions has been used in our
institution. However this scheme was abandoned because
of the high co-morbidity. Motamedinia et al. [10] found that
adjuvant BCG did not mitigate the risk of recurrence, RNUNetherlands. UTUC, upper tract urothelial cell carcinoma; URS,
l; PCTR, percutaneous tumour resection; Micr., microscopic.
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recommend a single admission of MMC because of the low
morbidity and the proven efficacy preventing bladder
tumour recurrences. Future studies will have to prove the
efficacy with UTUC as well.
4.6. Influence of surgical technique
Dilatation of a percutaneous tract in a tumour afflicted
calyx increases the risk for residual tumour in this calyx.
This should be avoided if possible. In order to achieve safe
access it is therefore important to use tumour free calices.
The direction of kidney entrance should be such that an
optimal view of the tumour afflicted site can be achieved.
This means that all dorsal and lateral calices are entry
candidates leading to a great variety in flank entry sites.
Obviously these are often above the 12th or 11th rib
because the position of the percutaneous tract is then
parallel to the renal axis, allowing for the largest exposure.
Ultrasonic guidance while establishing the percutaneous
tract allows a wide range of entry sites without compro-
mising other organs.
The main limiting factor in PCTR in the case of non-
invasive appearing tumours is the surface area afflicted
with tumour. We have not resected more than about 30% of
the pelvic wall at a time because of the risk of uncontrol-
lable bleeding. This means that in some cases multifocality
and tumour size can be an issue if the afflicted part of
the pelvic wall is too large. In all of the six cases where the
primary resection could not be radical, this was due to the
size of the tumour afflicted area of the pelvic wall.
Performing PCTR we have used a 23.5 Fr resectoscope
and tried to resect as much tumour tissue as possible
without damaging large and uncontrollable blood vessels.
The entire pelvic wall is either resected or, if unable to
appreciate the depth of resection, completely coagulated.
One has to bear in mind that coagulation effects are deeper
than the thickness of the pelvic wall. The procedure is done
with controlled water pressure and flow for sustained visi-
bility. The availability of bipolar equipment seems to have
increased the controllability, however this has not been
studied here; the settings were the same as with tran-
surethral bladder tumour resections. The limited space
within the collecting system calls for optimal visualisation
and approach of the tumour area, necessitating an optimal
angle of the percutaneous tract. It can therefore be
necessary to perform more than one PCTR in order to
achieve total removal of all tumour. In our series this was
the case with 2 patients, and it did not alter the outcome,
CSS and OS.
4.7. Learning curve
The PCTR technique, the great variety of the collecting
system anatomy and the low incidence of UTUC make that
the learning curve may take an entire career. This fact
makes exchange of experiences in patient selection, tech-
nique, adjuvant treatment and follow-up between centres
the more important. A wider application of PCTR will of
course increase the numbers and shorten the learning
curve.A well designed, multi-centre study is necessary to
formulate a more definite answer to the question so nicely
stated by Motamedinia et al. [10]: when deciding on
appropriate treatment of macroscopically non-invasive
UTUC, what is lost by electing endoscopic management
over immediate RNU? Can we minimise this possible loss by
refining selection criteria and improving imaging modal-
ities? The future will show if agreement on algorithms like
the one used in our institution is possible (Fig. 3).
5. Conclusion
In the management of UTUC endoscopic treatment,
particularly PCTR has shown to be an effective and safe
treatment option. In this series we preserved 70% of the
kidneys reducing the risk of CKD. Selection criteria and
patient counselling should be based primarily on urinary
tract imaging and secondarily on other factors such as
grade, co-morbidity, costs, surveillance burden, etc. The
selection criteria could be further refined. A study based on
randomisation of centres as a whole could be an option.
The long learning curve calls for intensive exchange and
cooperation between centres world wide.Conflicts of interest
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